Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2025-12-25 @ 1:33 AM
NCT ID:
NCT04901494
Eligibility Criteria:
Inclusion Criteria:
1. Age 55+
2. Diagnosis of mild cognitive impairment.
3. One year treatment with an SSRI prior to diagnosis of MCI or six months treatment after diagnosis of MCI for the intervention groups. No treatment with an SSRI prior to the diagnosis of MCI or after the diagnosis of MCI for the control group.
4. A minimum of two annual follow up evaluations.
Exclusion Criteria:
1. Patients with CNS infection or inflammation
2. HIV
3. Syphilis
4. Patients with poorly controlled Epilepsy based on the opinion of the investigator.
5. Patients with space occupying lesions of the brain (glioma, meningioma, brain metastasis).
6. Patients with systemic inflammatory condition or cancer undergoing chemotherapy or on chronic immune modulatory treatments.
7. Blind patients that were not able to complete a cognitive assessment.
8. Patients with chronic pain who are on excluded pain medications.
9. Patients with Attention Deficit Disorder that require the use of stimulant medications.
10. Patients with Traumatic Brain Injury.
11. Patients with Cerebral Aneurysm Rupture.
12. Patients with chronic psychiatric conditions, unless in remission. Recurrent chronic psychiatric condition in relapse, chronic recurrent Major Depression in relapse, chronic recurrent bipolar disorder, chronic relapsing schizoaffective disorder and chronic recurrent anxiety disorder requiring chronic use of benzodiazepines are exclusionary.
13. Patients taking an excluded medication.
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT04901494
Study Brief:
Protocol Section:
NCT04901494